Biomarker-Guided Heart Failure Management: Why Certainty of Evidence Matters
Study at a glance
- Publication type: Systematic review and meta-analysis of randomised trials
- What it examined: This review compared BNP or NT-proBNP-guided management with clinically guided management in heart failure, pooling randomised controlled trials.
- Key point: The authors reported a trend toward benefit but rated the certainty of the available evidence as very low using the GRADE approach. That uncertainty is as important as the pooled estimate when interpreting the review.
Why it matters
Evidence-based practice requires attention to study quality and certainty, not only whether a result appears favourable.
Source
Biomarker-Guided Versus Clinically Guided Management Strategies for Heart Failure: A Systematic Review and Meta-Analysis. PMID: 41923737. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.

Previous Post
HFpEF Pharmacotherapy: What a Network Meta-analysis Compared
Next Post
Predicting Incident Heart Failure: How Well Do Risk Models Validate?

